GSK1379725A (AU1)是一种选择性BPTF（溴结构域PHD指转录因子）配体，其结合亲和力（Kd）为2.8μM。
Cas No.:1802251-00-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
GSK1379725A (AU1)is a selective BPTF (bromodomain PHD finger transcription factor) ligand with a binding affinity (Kd) of 2.8µM[1-2]. GSK1379725A can be used to study the role of BPTF in the mechanism of cancer development and progression[3-4].
In vitro, 4T1 and E0771-LMB triple-negative breast cancer cells were pretreated with GSK1379725A (2.5µM) for 12 hours, followed by co-treatment with chemotherapeutic drugs (such as vinorelbine, vinblastine, doxorubicin, etc.) for 96 hours. GSK1379725A significantly enhanced the cytotoxic effects of the chemotherapeutic agents on the cells and induced apoptosis and senescence[5]. K562 (chronic myeloid leukemia cells) and MCF-7 (hormone-positive breast cancer cells) were treated with GSK1379725A (5µM) for 72 hours. GSK1379725A significantly inhibited cell viability[6].
In vivo, BALB/c nude mice implanted with METTL14-/- Luc-Renca renal cancer cells (a murine renal cancer cell line) were treated with GSK1379725A (13.2mg/kg) via intraperitoneal injection three times per week for 5 weeks. GSK1379725A significantly inhibited distal lung metastasis of METTL14-deficient renal cancer cells and improved the survival prognosis of tumor-bearing mice[7]. BALB/c nude mice bearing subcutaneous xenografts of MGC803 gastric cancer cells were treated with GSK1379725A (5mg/kg) via intraperitoneal injection once daily for 30 days. GSK1379725A monotherapy significantly inhibited tumor growth and demonstrated synergistic antitumor effects when combined with Erlotinib (20mg/kg)[8].
References:
[1] Urick AK, Hawk LM, Cassel MK, et al. Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules. ACS Chem Biol. 2015 Oct 16;10(10):2246-56.
[2] Tyutyunyk-Massey L, Sun Y, Dao N, et al. Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor. Mol Cancer Res. 2021 Aug;19(8):1338-1349.
[3] Jiang C, Yang Y, He S, et al. BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma. Biol Proced Online. 2023 May 11;25(1):11.
[4] Gao S, Zhang W, Ma J, et al. PHF6 recruits BPTF to promote HIF-dependent pathway and progression in YAP-high breast cancer. J Transl Med. 2023 Mar 26;21(1):220.
[5] Sinanian MM, Rahman A, Elshazly AM, et al. A BPTF Inhibitor That Interferes with the Multidrug Resistance Pump to Sensitize Murine Triple-Negative Breast Cancer Cells to Chemotherapy. Int J Mol Sci. 2024 Oct 22;25(21):11346.
[6] Kirberger SE, Ycas PD, Johnson JA, et al. Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor. Org Biomol Chem. 2019 Feb 13;17(7):2020-2027.
[7] Zhang C, Chen L, Liu Y, et al. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma. Theranostics. 2021 Jan 26;11(8):3676-3693.
[8] Li F, Yu J, Pan T, et al. BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis. Adv Sci (Weinh). 2023 Dec;10(34):e2303091.
GSK1379725A (AU1)是一种选择性BPTF（溴结构域PHD指转录因子）配体，其结合亲和力（Kd）为2.8μM[1-2]。GSK1379725A可用于研究BPTF中癌症发生发展中的作用机制[3-4]。
在体外，GSK1379725A（2.5μM）预处理4T1和E0771-LMB三阴性乳腺癌细胞12小时，随后与化疗药物（如长春瑞滨、长春碱、多柔比星等）共同处理96小时。GSK1379725A显著增强化疗药物对细胞的毒性作用，并诱导细胞凋亡和衰老[5]。GSK1379725A(5μM)处理K562（慢性髓系白血病细胞）和MCF-7（激素阳性乳腺癌细胞）72小时。GSK1379725A显著抑制细胞活力 [6]。
在体内，GSK1379725A（13.2mg/kg）每周三次腹腔注射，用于处理植入METTL14-/- Luc-Renca肾癌细胞（小鼠肾癌细胞系）的BALB/c裸鼠，持续5周。GSK1379725A显著抑制了METTL14缺陷肾癌细胞的远端肺转移，并改善了荷瘤小鼠的生存预后[7]。GSK1379725A（5mg/kg）每日一次腹腔注射，用于处理携带MGC803胃癌细胞皮下移植瘤的BALB/c裸鼠，持续30天。GSK1379725A单药治疗显著抑制了肿瘤生长，并且与厄洛替尼（20mg/kg）联合使用时表现出协同抗肿瘤效应[8]。
| Cell experiment [1]: | |
Cell lines | 4T1 and E0771-LMB murine triple-negative breast cancer (TNBC) cells; MDA-MB-231 human TNBC cells |
Preparation Method | Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were pre-treated with 2.5μM GSK1379725A overnight (≥12 hours) and then treated with serially diluted chemotherapeutic agents with or without 2.5μM GSK1379725A for 96 hours. |
Reaction Conditions | 2.5μM; 96h |
Applications | GSK1379725A significantly sensitized 4T1 and E0771-LMB cells to P-glycoprotein (P-gp) substrate chemotherapeutic agents (e.g., vinorelbine, vinblastine, paclitaxel, doxorubicin), reducing IC50 values by 2- to 8-fold, but did not sensitize to non-P-gp substrates (5-FU, cisplatin) or MDA-MB-231 cells lacking P-gp expression. GSK1379725A induced apoptosis and senescence in combination treatments and inhibited P-gp efflux pump function, as demonstrated by increased calcein-AM retention. |
| Animal experiment [2]: | |
Animal models | BALB/c nude mice |
Preparation Method | Mice were subcutaneously injected with MGC803 gastric cancer cells. Once tumors reached a measurable size, mice were intraperitoneally administered GSK1379725A (5mg/kg), Erlotinib (20mg/kg), GSK1379725A plus Erlotinib, or a vehicle control for 30 days. Tumor growth was monitored, and mice were sacrificed for analysis. |
Dosage form | 5mg/kg/day; i.p.; 30 days. |
Applications | The combination of GSK1379725A and Erlotinib synergistically inhibited subcutaneous tumor growth in MGC803 xenograft models, leading to significantly lower tumor weight and volume compared to vehicle control or single-agent treatment groups. Mice in the GSK1379725A plus Erlotinib group also demonstrated the best survival outcome. |
References: | |
| Cas No. | 1802251-00-8 | SDF | |
| 别名 | AU1 | ||
| Canonical SMILES | O=C(OC)C1=CC=CC(NC(NC2CN(C3=NC(NC4=CC=C(F)C=C4)=NC=C3)CC2)=O)=C1 | ||
| 分子式 | C23H23FN6O3 | 分子量 | 450.47 |
| 溶解度 | DMSO: 83.33 mg/mL (184.98 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2199 mL | 11.0995 mL | 22.199 mL |
| 5 mM | 444 μL | 2.2199 mL | 4.4398 mL |
| 10 mM | 222 μL | 1.11 mL | 2.2199 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet